Endocannabinoids have also been explored as a potential treatment for atopic dermatitis, particularly CB1 agonists which have potential to reduce inflammation by suppressing mast cell activation in AD mouse models [70]. This evidence concerns the gene CNR1 and Alzheimer disease.